MODULEX
5.5.2022 15:02:06 CEST | Business Wire | Pressemeddelelse
Modulex A/S er globalt markedsledende inden for visuel kommunikation med 30 salgsenheder og flere produktionsfaciliteter rundt omkring i verden. Modulex A/S leverer wayfinding og arkitektoniske skilteløsninger samt multi-site brandimplementering og er den førende producent af systemskilte på verdensplan.
Koncernen sluttede 2021 med et EBITDA resultat på 17 mio. kr.
Mens koncernen som helhed leverede et flot resultat, er flere salgsenheder som fx Modulex Hospitality, der primært leverer skilteløsninger til internationale hotelkæder og ferieresorts, fortsat alvorligt påvirket af den globale pandemi og er først begyndt at se tegn på opsving i år. På trods af at det mange steder stadig er vanskeligt fysisk at besøge projekter og kunder, holdt de lokale kontorer verden over fast. Globalt set har Modulex Gruppen haft det bedste år i koncernens historie og har i løbet af året leveret og implementeret nogle meget store virksomhedsrebrands i både USA og Vesteuropa.
”Set i lyset af det pres, vi oplever på leveringstider og råmaterialer som aluminium, er vores resultat meget flot," siger Ketil M. Staalesen, administrerende direktør og hovedaktionær i Modulex Gruppen. "Vores produktionsteam udnyttede partnerskaber etableret gennem mange års samarbejde til at sikre, at vi kunne imødekomme vores kunders krav. Vores forretningsudviklingsstrategi fokuserede på at fremme miljøvenlige produkter som Etronit og Greenbond™, som er mindre påvirket af leveringsmæssige udfordringer."
Modulex Gruppen vil i 2022 fokusere på design-build-strategien, globale kunder, mere miljøvenlige produkter og lanceringen af den cloud-baserede projektstyringssoftware e-Modulex. Modulex har allerede indgået nye.
"2022 bliver stadig en udfordring," siger Staalesen. “Men vores solide forretningsstrategi og vores ledelsesteams evne til at kæmpe gennem de seneste to år inspirerer mig. Jeg kunne ikke være mere stolt af dem, og jeg forventer, at vi overgår vores forventninger i år."
Om Modulex Gruppen:
Modulex Gruppen, som blev grundlagt i 1963 af LEGO-koncernen og som siden 2009 har været ejet af ledelsen samt andre eksterne investorer, er global markedsleder inden for visuel kommunikation og brandimplementering. Med rod i dansk designekscellence og et modulært skiltekoncept har Modulex udviklet sin platform yderligere med design, wayfinding, brugerdefinerede løsninger og brandimplementeringer. Fabrikken i Billund, som er ISO 9001-certificeret, lancerede i 2019 en mere miljøvenlig produktlinje. Modulex Billund blev tildelt Green Network-diplomet for niende år i træk. Modulex Gruppen har fem fabrikker globalt. Koncernen er repræsenteret i over 300 byer på tværs af 45 lande, hvilket giver Modulex Gruppen den nødvendige rækkevidde og evne til at leve op til sit løfte om global vision, lokal rækkevidde og én virksomhed.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220505005139/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum